This promotional material is intended for UK healthcare professionals (HCPs) experienced in the diagnosis and management of migraine only. Prescribing Information and adverse event reporting information can be found below.
.png){kind=logo}
In episodic migraine, AQUIPTA® is generally well tolerated1
- The safety profile of AQUIPTA® was evaluated in 2,657 patients with migraine who received at least one dose1
- The most commonly reported adverse drug reactions were nausea (7%), constipation (7%) and fatigue/somnolence (5%)1
- The majority of cases were mild and none were serious1
- The adverse reaction that most commonly led to treatment discontinuation was nausea (0.6%)1
ADVANCE study
In the 12-week pivotal ADVANCE trial in patients with 4–14 migraine days/month (N=910), AQUIPTA® 60 mg once‑daily (n=231) was generally well tolerated versus placebo (n=222) across 12 weeks.2*
- Rates of adverse reactions leading to discontinuation were similar in the placebo (2.7%) and AQUIPTA® 60 mg once‑daily (2.6%) arms2
- No serious adverse events related to AQUIPTA® or placebo were reported in either arm2
Adverse events occurring in ≥4% of patients in any trial group (safety population)2
Adapted from Ailani J et al. 20212
*AQUIPTA® was evaluated for the prophylaxis of migraine in patients with 4–14 migraine days/month. The ADVANCE study enrolled patients who met International Classification of Headache Disorders criteria for a diagnosis of migraine with or without aura. Patients with myocardial infarction, stroke or transient ischaemic attacks within 6 months prior to screening were excluded.1,3
UK-AQP-250087 | Date of preparation: March 2025.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
